aci-toxicity-management_-_Edited.png

Tuesday, June 16, 2026 | 1–5 P.M. ET
Live via Zoom Webinar

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of toxicity management. FREE for healthcare professionals, students, patients and patient advocates.

Registration Available Soon

Program Organizers

Lisa Kottschade, APRN, MSN, CNP, FAPO
Mayo Clinic

Kerry Reynolds, MD
Massachusetts General Hospital

Ryan Sullivan, MD
Harvard School of Medicine

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2026 ACI series.

Log in to see this information

Either the content you're seeking doesn't exist or it requires proper authentication before viewing.

Program Agenda – Coming Soon

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Identify appropriate clinical management of common immune-related adverse events resulting from cancer immunotherapy treatments, including immune checkpoint inhibitors and cell therapies.

  • Outline best practices for multidisciplinary management of patients receiving cancer immunotherapy treatment.

  • Describe management approaches for difficult or refractory immune-related adverse events.

Accreditation Information – Coming Soon

Disclosures and ADA Info

Disclosure of Conflicts of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Avoid Fraudulent ACI Websites

Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.

All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org. If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.

The 2026 ACI series is jointly provided by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer.